Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
ANAPTYSBIO, INC President and CEO Daniel Faga reported compensation-related stock option changes rather than open-market share trades. On April 20, 2026, he both acquired and disposed of multiple employee stock options covering shares of AnaptysBio common stock.
Footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted so it became an option on both companies’ shares. As a result, Faga acquired new options to buy AnaptysBio common stock at exercise prices such as $10.87, $15.53, $17.02, $22.31, and $32.17 per share, with corresponding dispositions of prior awards back to the issuer.
Several of these options are described as fully vested or vesting 25% on specific January dates with the balance vesting in equal monthly installments over 48 months, contingent on his continued service. The filing reflects grants, adjustments, and issuer-related dispositions of options, not open-market buying or selling of common stock.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.
ANAPTYSBIO, INC director Susannah Gray filed an initial Form 3 reporting her status as a director of the company. The filing does not list any reportable transactions or equity holdings, indicating this is a baseline disclosure of insider status rather than a trading event.
ANAPTYSBIO director John P. Schmid sold 20,645 shares of Common Stock in open-market transactions. All sales occurred on March 30, 2026 at weighted average prices ranging from $55.7087 to $57.3989 per share, within overall trade ranges of $55.20 to $57.92.
After these sales, Schmid directly holds 31,622 shares of ANAPTYSBIO Common Stock, according to the filing.
ANAPTYSBIO, INC, identified as a ten percent owner of First Tracks Biotherapeutics, Inc., filed an initial ownership report. In connection with the spin-off of First Tracks under a Separation and Distribution Agreement dated April 1, 2026, ANAPTYSBIO owns all 100 outstanding shares of First Tracks common stock.
ANAPTYSBIO, INC President and CEO Daniel Faga received 34,300 performance-based restricted stock units (PSUs) after the compensation committee certified that specific performance goals were achieved on March 25, 2026. Each PSU represents a right to receive one share of common stock.
On March 27, 2026, Faga sold an aggregate of 17,679 shares of common stock in multiple open-market transactions at weighted-average prices ranging from the mid‑$50s to mid‑$60s per share. According to the disclosure, these sales were solely to cover tax withholding obligations from the PSU vesting and were not discretionary trades.
After these grant and tax-related sales, Faga holds 495,965 shares of AnaptysBio common stock directly, indicating that the transactions reflect routine compensation vesting and associated tax settlement rather than a change in his core equity position.
AnaptysBio is executing a major restructuring built around spinning off First Tracks Biotherapeutics and returning capital to shareholders. The board approved a pro rata spin-off of First Tracks, with holders of AnaptysBio stock receiving one First Tracks share for each AnaptysBio share held on April 6, 2026, with distribution expected before U.S. market open on April 20, 2026 and First Tracks trading on Nasdaq under “TRAX.”
To fund the new company, First Tracks and EcoR1 Capital agreed to a $145 million private placement at $13.81 per share, including 5,791,478 primary shares generating about $80 million in gross proceeds for First Tracks and 4,705,576 secondary shares sold by EcoR1. AnaptysBio also terminated its prior at‑the‑market equity program and authorized a stock repurchase plan of up to $100 million. Governance changes include appointing Susannah Gray as a director and putting executive transition and separation agreements in place for Dennis Mulroy and Eric Loumeau tied to the spin-off.
AnaptysBio Inc filed an Amendment No. 1 to Schedule 13G/A reporting that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class after an internal realignment. The filing states Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
AnaptysBio, Inc. is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its wholly owned pipeline includes rosnilimab, which delivered statistically significant Phase 2b results in moderate-to-severe rheumatoid arthritis, plus ANB033 in Phase 1b trials for celiac disease and eosinophilic esophagitis, and ANB101 in a Phase 1 trial targeting BDCA2 on plasmacytoid dendritic cells.
The company also earns milestones and royalties from partnered antibodies. GSK’s PD‑1 drug Jemperli generated $1.1 billion in 2025 sales, up from $598.0 million in 2024. Vanda holds global rights to imsidolimab for generalized pustular psoriasis, with a BLA accepted by the FDA and a target action date of December 12, 2026.
In September 2025, AnaptysBio’s board approved plans to pursue a separation into two independent public companies, one focused on managing Jemperli and imsidolimab financial collaborations and one focused on advancing its clinical immunology pipeline. The separation is expected in the second quarter of 2026, subject to board approval and SEC registration effectiveness.